[Capsid protein VP1]: Capsid proteins VP1, VP2, and VP3 form a closed capsid enclosing the viral positive strand RNA genome . All these proteins contain a beta-sheet structure called beta-barrel jelly roll . Together they form an icosahedral capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with a diameter of approximately 300 Angstroms . VP1 is situated at the 12 fivefold axes, whereas VP2 and VP3 are located at the quasi-sixfold axes . The naked capsid interacts with the host receptor HAVCR1 to provide virion attachment to and probably entry into the target cell . .; [Capsid protein VP2]: Capsid proteins VP1, VP2, and VP3 form a closed capsid enclosing the viral positive strand RNA genome . All these proteins contain a beta-sheet structure called beta-barrel jelly roll . Together they form an icosahedral capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with a diameter of approximately 300 Angstroms . VP1 is situated at the 12 fivefold axes, whereas VP2 and VP3 are located at the quasi-sixfold axes . The naked capsid interacts with the host receptor HAVCR1 to provide virion attachment to and probably entry into the target cell . .; [Capsid protein VP3]: Capsid proteins VP1, VP2, and VP3 form a closed capsid enclosing the viral positive strand RNA genome . All these proteins contain a beta-sheet structure called beta-barrel jelly roll . Together they form an icosahedral capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with a diameter of approximately 300 Angstroms . VP1 is situated at the 12 fivefold axes, whereas VP2 and VP3 are located at the quasi-sixfold axes . The naked capsid interacts with the host receptor HAVCR1 to provide virion attachment to and probably entry into the target cell . .; [Capsid protein VP0]: VP0 precursor is a component of the immature procapsids. .; [Capsid protein VP4]: Plays a role in the assembly of the 12 pentamers into an icosahedral structure. Has not been detected in mature virions, supposedly owing to its small size. .; [Protein VP1-2A]: Precursor component of immature procapsids that corresponds to an extended form of the structural protein VP1 . After maturation, possibly by the host Cathepsin L, the assembly signal 2A is cleaved to give rise to the mature VP1 protein . .; [Protein 2B]: Functions as a viroporin . Affects membrane integrity and causes an increase in membrane permeability . Involved in host intracellular membrane rearrangements probably to give rise to the viral factories . Does not disrupt calcium homeostasis or glycoprotein trafficking . Antagonizes the innate immune response of the host by suppressing IFN-beta synthesis, which it achieves by interfering with the RIG-I/IFIH1 pathway . .; [Protein 2BC]: Affects membrane integrity and causes an increase in membrane permeability. .; [Protein 2C]: Associates with and induces structural rearrangements of intracellular membranes . Displays RNA-binding activity . .; [Protein 3ABC]: The precursor 3ABC is targeted to the mitochondrial membrane where protease 3C activity cleaves and inhibits the host antiviral protein MAVS, thereby disrupting activation of IRF3 through the IFIH1/MDA5 pathway . In vivo, the protease activity of 3ABC precursor is more efficient in cleaving the 2BC precursor than that of protein 3C. The 3ABC precursor may therefore play a role in the proteolytic processing of the polyprotein . .; [Protein 3AB]: Interacts with the 3CD precursor and with RNA structures found at both the 5''- and 3''-termini of the viral genome . Since the 3AB precursor contains the hydrophobic domain 3A, it probably anchors the whole viral replicase complex to intracellular membranes on which viral RNA synthesis occurs . .; [Protein 3A]: May serve as membrane anchor to the 3AB and 3ABC precursors via its hydrophobic domain . May interact with RNA . .; [Viral protein genome-linked]: Acts as a primer for viral RNA replication and remains covalently bound to viral genomic RNA. VPg is uridylylated prior to priming replication into VPg-pUpU. The VPg-pUpU is then used as primer on the genomic RNA poly(A) by the RNA-dependent RNA polymerase to replicate the viral genome. .; [Protease 3C]: Cysteine protease that generates mature viral proteins from the precursor polyprotein . In addition to its proteolytic activity, it binds to viral RNA, and thus influences viral genome replication . RNA and substrate bind cooperatively to the protease . Cleaves IKBKG/NEMO to impair innate immune signaling . Cleaves host PABPC1 which may participate in the switch of viral translation to RNA synthesis . .; [Protein 3CD]: Interacts with the 3AB precursor and with RNA structures found at both the 5''- and 3''-termini of the viral genome . Disrupts TLR3 signaling by degrading the host adapter protein TICAM1/TRIF . .; RNA-directed RNA polymerase 3D-POL replicates genomic and antigenomic RNA by recognizing replications specific signals. .

p08617

Genome polyprotein [Cleaved into: Capsid protein VP0 (VP4-VP2); Capsid protein VP4 (P1A) (Virion protein 4); Capsid protein VP2 (P1B) (Virion protein 2); Capsid protein VP3 (P1C) (Virion protein 3); Protein VP1-2A (VP1-pX); Capsid protein VP1 (P1D) (Virion protein 1); Assembly signal 2A (pX); Protein 2BC; Protein 2B (P2B); Protein 2C (P2C) (EC 3.6.1.15); Protein 3ABCD (P3); Protein 3ABC; Protein 3AB; Protein 3A (P3A); Viral protein genome-linked (VPg) (Protein 3B) (P3B); Protein 3CD; Protease 3C (P3C) (EC 3.4.22.28) (Picornain 3C); RNA-directed RNA polymerase 3D-POL (P3D-POL) (EC 2.7.7.48)],Genome polyprotein, Capsid protein VP2, P1B, Virion protein 2

Human hepatitis A virus genotype IB (isolate HM175) (HHAV) (Human hepatitis A virus (isolate Human/Australia/HM175/1976))

ELISA,Neutralization

ELISA 1:5000-1:20000
Neutralization,The optimal dilutions should be determined by the end user.

252kD

Human

Monoclonal

R256

IgG1

Protein A/G purified from cell culture supernatant.

>95% as determined by SDS-PAGE.

0.01M PBS, pH 7.4.

1 mg/ml

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4℃ short term (1-2 weeks). Store at -20℃ 12 months.

For research use only. Not suitable for clinical or therapeutic use.